Read on Twitter
2020 has been challenging, so I want to end on a high note with all the publications I have contributed to this year #teamwork #stats #clinicaltrials @ICR_CTSU 
1/12 Main results of the TOPARP-B trial, phase 2 of #olaparib in 98 patients with metastatic castration-resistant #prostatecancer with DNA repair gene aberrations @quimmateo @jodebon @scarreira1 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30684-9/fulltext
2/12 TOPARP-B screened 711 patients for DDR aberrations â this large cohort of patients contributed to further study the genomics of lethal primary #prostatecancer @quimmateo @georgeseed @scarreira1 @jodebon
https://doi.org/10.1172/JCI132031
https://doi.org/10.1172/JCI132031
3/12 Patients whose tumours presented CDK12 aberrations had a poor outcome in TOPARP-B, so were included in a pooled analysis to further understand their clinical, molecular, and immune characteristics @PasRescigno @boragurel @jodebon https://clincancerres.aacrjournals.org/content/early/2020/10/22/1078-0432.CCR-20-2371
4/12 Phase 1 results of the RE-AKT trial, investigating enzalutamide and the AKT inhibitor #capivasertib in patients with advanced #prostatecancer which had stopped responding to hormone therapy @PasRescigno @HollyTovey @jodebon https://doi.org/10.1016/j.annonc.2020.01.074
5/12 PIVOTALboost is a phase 3 trial investigating advanced #radiotherapy techniques for #prostateCancer treatment. It is open to recruitment at 38 UK sites â protocol available from: https://www.sciencedirect.com/science/article/pii/S2405630820300690?via%3Dihub
6/12 Main results of the 111 phase 3, single arm trial, showing that chemotherapy in #TesticularCancer can be reduced without increasing the risk of relapse @robert_huddart https://www.europeanurology.com/article/S0302-2838(19)30895-4/fulltext
7/12 Main results of the CALIBER phase 2 trial, investigating whether chemoablation might allow people to avoid surgery for low risk recurrent non-muscle invasive #bladdercancer #NMIBC @ahmostafid https://doi.org/10.1111/bju.15038
8/12 Health-economics sub-study of the BOXIT trial, that evaluated the addition of celecoxib to standard treatment for patients with #NMIBC #bladdercancer and an intermediate or a high risk of recurrence Prof J Kelly @MJSculpher @mfosoares @drtanws https://doi.org/10.1016/j.clgc.2019.12.004
9/12 Quality of life sub-study of the BC2001 trial, the largest randomised trial of bladder-sparing treatment for muscle-invasive #bladdercancer #MIBC @robert_huddart @Prof_Nick_James https://www.europeanurology.com/article/S0302-2838(19)30840-1/fulltext
10/12 Exploratory analysis on the impact of neoadjuvant chemotherapy on #bladderbancer chemoradiotherapy in BC2001, which was feasible and well tolerated @ProfSyedHussain @Prof_Nick_James @robert_huddart https://www.sciencedirect.com/science/article/pii/S0302283820309374
11/12 Accepted for publication (just checking the proofs!), a meta-analysis of BC2001 and BCON trials to investigate the role of hypofractionacted #radiotherapy on invasive #bladdercancer @achoud72 @syeepei @robert_huddart @Prof_Nick_James https://twitter.com/NPortaStat/status/1311236972288053248?s=20
12/12 Accepted for publication, secondary analyses of the DISCOVAR trial , exploring MRI imaging biomarkers of response to neoadjuvant chemotherapy in #ovariancancer â soon available! JessWinfield NanditadeSouza @BanerjeeSusana.
I am really grateful for the generosity of our clinical collaborators, the amazing #teamwork @ICR_CTSU and the support of @EmmaHall71 and Judith Bliss. In the pipeline for 2021, TOPARP-B translational work, RE-AKT phase 2 cohorts main results, NICAM & EPHOS-B publications
And importantly for me, 2021 brings more exciting work on imaging biomarkers in #prostatecancer, #myeloma and #colorectalcancer with @Prof_DM_Koh CMessiou JOâConnor @MyMKaiser @BlackledgeICR @Nina18205 #teamimaging #bringiton2021 #HappyNewYear \\end 
Shame on me, I forgot to mention, more imaging biomarker work on #bladdercancer with @Shaista_Hafeez! #teamimaging
